Idexx Laboratories (IDXX) fundamentals: P/E, valuation, undervalued?
Idexx Laboratories · Health Care · ref. ETF XLV · price $520.31
In short — Idexx Laboratories trades at 37.0× earnings (P/E), 31.1× forward, with a net margin of 25.0 % and revenue growth of +10 %. Read: Fairly valued (P/E 31 in line with ~18% growth (PEG 1.8)).
Is Idexx Laboratories stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$520.31-18.3% over range
Oct 14, 25low $504.7 · high $766.68Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
25% recommend buying · 4 analysts
Valuation : Fairly valued — P/E 31 in line with ~18% growth (PEG 1.8)
Valuation
37.0
P/E (price/earnings)
31.1
Forward P/E
2.10
PEG
25.4
Price/book (P/B)
$41.0B
Market cap
14.07
EPS
Profitability & growth
25.0 %
Net margin
+10 %
Revenue growth
+18 %
Earnings growth
$1.1B
Total debt
Idexx Laboratories income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $3.4B | $679M | 20.2 % |
| 2023 | $3.7B | $845M | 23.1 % |
| 2024 | $3.9B | $888M | 22.8 % |
| 2025 | $4.3B | $1.1B | 24.6 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Idexx Laboratories's P/E and is the stock undervalued? What's a good P/E?
Idexx Laboratories's P/E is 37.0 (forward 31.1). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Fairly valued".
Is Idexx Laboratories profitable?
Idexx Laboratories has a net margin of 25.0 % (EPS 14.07). The company is profitable.
Is IDXX stock expensive?
Our read: "Fairly valued" — P/E 31 in line with ~18% growth (PEG 1.8). Cross-check with growth and sector.
💬 A question about Idexx Laboratories? The JPI assistant answers using our backtest data.
Keep exploring Idexx Laboratories